Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, 210002, China.
Division of Cardiovascular Imaging, Department of Radiology and Radiological Science, Medical University of South Carolina, Ashley River Tower, MSC 226, 25 Courtenay Dr, Charleston, SC, 29401, USA.
Eur Radiol. 2018 Apr;28(4):1585-1593. doi: 10.1007/s00330-017-5109-0. Epub 2017 Nov 2.
To determine whether intravenous iodinated contrast material administration increases the risk of acute kidney injury (AKI) in patients with nephrotic syndrome undergoing contrast-enhanced CT.
Patients with nephrotic syndrome undergoing contrast-enhanced CT were retrospectively identified (n = 701). Control group consisted of patients with nephrotic syndrome receiving non-contrast CT (n = 1053). Two different 1:1 propensity score matching models using three or 10 variables were developed for each estimated glomerular filtration (eGFR) subgroup. Incidence of post-CT AKI for the two groups was assessed and compared by standard AKI criteria and Acute Kidney Injury Network (AKIN) criteria.
After matching with three variables, the AKI incidence in the contrast-enhanced CT and non-contrast CT groups was 2.7% vs 2.5% (standard AKI criteria) and 4.2% vs. 6.7% (AKIN criteria) (p = 1.00 and 0.05), respectively. After matching with 10 variables, AKI incidences were 3.1% vs. 2.6% (standard AKI criteria) and 4.1% vs. 7.4% (AKIN criteria) (p = 0.72 and 0.03), respectively. AKI incidences of each eGFR subgroup in the contrast-enhanced CT group were not higher than in the non-contrast CT group (lowest p = 0.46).
Intravenous contrast material administration during CT was not found to be a risk factor for AKI in this large cohort of patients with nephrotic syndrome.
• AKI incidence of contrast-enhanced CT and non-contrast CT had no difference. • AKI incidences of eGFR subgroup in contrast-enhanced CT were not increased. • Studies without a non-contrast CT control group may overestimate CIN incidence.
确定在接受对比增强 CT 的肾病综合征患者中,静脉内碘造影剂的使用是否会增加急性肾损伤 (AKI) 的风险。
回顾性确定接受对比增强 CT 的肾病综合征患者(n=701)。对照组由接受非对比 CT 的肾病综合征患者组成(n=1053)。对于每个估计肾小球滤过率 (eGFR) 亚组,使用三个或十个变量开发了两个不同的 1:1 倾向评分匹配模型。通过标准 AKI 标准和急性肾损伤网络 (AKIN) 标准评估和比较两组 CT 后 AKI 的发生率。
与三个变量匹配后,增强 CT 和非增强 CT 组的 AKI 发生率分别为 2.7%比 2.5%(标准 AKI 标准)和 4.2%比 6.7%(AKIN 标准)(p=1.00 和 0.05)。与十个变量匹配后,AKI 发生率分别为 3.1%比 2.6%(标准 AKI 标准)和 4.1%比 7.4%(AKIN 标准)(p=0.72 和 0.03)。增强 CT 组的每个 eGFR 亚组的 AKI 发生率均低于非增强 CT 组(最低 p=0.46)。
在这项大型肾病综合征患者队列中,CT 期间静脉内造影剂的使用并未发现是 AKI 的危险因素。
• 增强 CT 和非增强 CT 的 AKI 发生率无差异。• 增强 CT 中 eGFR 亚组的 AKI 发生率没有增加。• 没有非对比 CT 对照组的研究可能会高估 CIN 的发生率。